BLAINTRAVENOUSVIALPriority Review
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTASCINT (capromab pendetide) is a radioimmunoconjugate diagnostic agent approved in 1996 for imaging prostate cancer. It is an indium-111 labeled monoclonal antibody that binds to prostate-specific membrane antigen (PSMA) to detect metastatic prostate cancer. The drug enables staging and detection of occult disease in men with elevated PSA or biopsy-proven prostate cancer.
LOE Approaching
As a mature diagnostic product approaching loss of exclusivity, this asset likely operates with a lean, specialized commercial team focused on maintaining market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy
Started Jan 2015
19 enrolled
Prostate Cancer
Career Relevance
PROSTASCINT offers minimal career growth opportunities given its late-stage lifecycle and zero linked job openings. This asset is best suited for professionals seeking to maintain expertise in oncology diagnostics or transition roles rather than launch or high-growth experiences.
Diagnostic Product Manager
Worked on PROSTASCINT at Biocytogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.